Table 1 The characteristics of included studies for meta-analysis. (CS/ET)
From: The efficacy of cytoreductive surgery for oligometastatic prostate cancer: a meta-analysis
Study | Country | Sample size | Age (median) | Interventions | T-stage | N-stage | M-stage (number of metastases) |
|---|---|---|---|---|---|---|---|
Jang et al. [28] | Korea | 38/41 | 65/71 | RARP/ADT | T ≤ cT2 5/2 T ≥ cT3 33/39 | cN0 21/15 cN1 17/26 | ≤ 5 |
Steuber et al. [27] | Germany | 43/40 | 65/70 | CRP/ADT | T ≤ cT2 20/9 cT3a/b 23/31 | IQR 2–7 | = 1 29/16 = 2 9/13 = 3 5/11 |
Sheng et al. [26] | China | 11/13 | NA | Cryosurgery/ADT | NA | NA | ≤5 |
Heidenreich et al. [25] | Germany | 23/38 | 61/64 | CRP/ADT | T ≤ cT2 7/10 T3a/b 16/24 cT4 0/4 | NA | ≤5 |
Steuber et al. [24] | Germany | 38/38 | 65/63 | RP/ADT | T1c 8/8 T ≤ cT2 19/19 T ≥ cT3 11/11 | Range 1–6 | NA |
Engel et al. [23] | Germany | 132/41 | NA | RP/ADT | NA | Range 2–3 | 0 |
Grimm et al. [29] | Germany | 27/9 | 64/63 | RP/ADT | NA | pN1 27/9 | NA |
Ghavamian et al. [22] | USA | 79/79 | 65/66 | RP/Orchiectomy | T ≤ cT2 42/35 T ≥ cT3 37/44 | n = 1 16/16 n = 2 17/16 n ≥ 3 46/47 | NA |
Schmeller and Lubos [21] | Germany | 39/37 | 62/67 | RP/ADT | T ≤ cT2 9 /16 T ≥ cT3 30/21 | pN1 27/21 pN2 12/16 | 0 |
Cadeddu et al. [20] | USA | 19/19 | 59/59 | RP/NA | T ≤ cT2 16/19 T ≥ cT3 3/0 | NA | 0 |